The content on this site is intended for healthcare professionals only
Dr Loi speaks at a SABCS 2017 press session about data presented from the phase Ib/II PANACEA trial.
She describes how a combination of pembrolizumab and trastuzumab, tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab.
Read the news story for more.
ASCO 2026: Latest updates in mRCC
The added value of integrative medicine
Insights into germline genetic screening of breast cancer patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
